RxDoctor Payments Data

Sandy Hemric-Bryant, NP

Family · Mount Airy, NCNPI 1205546207

Payments from drug & device makers

$1,004in general payments, 2019–2025

Across 55 payments — averaging $18.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$146
  • Axsome Therapeutics, Inc.$135
  • Amgen$116
  • Lilly USA, LLC$73
  • Exact Sciences$70
  • Novo Nordisk$70
  • plus $394 from 12 others

What the payments were for

  • Food & beverage$1,004100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,004 in reported general payments places this provider in the 70th percentile of 4,522 family providers in North Carolina.

See all family providers in North Carolina

Medicare billing

Part B allowed, 2024
$35,783
Medicare patients
210
Services billed
431

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban117$109,427
OzempicSemaglutide63$68,580
FarxigaDapagliflozin Propanediol44$47,062
JardianceEmpagliflozin37$45,945
JanuviaSitagliptin Phosphate35$36,695
LinzessLinaclotide27$34,113
TrulicityDulaglutide32$32,285
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$18,902
Combivent RespimatIpratropium/Albuterol Sulfate17$16,149
MyrbetriqMirabegron11$12,509
Breztri AerosphereBudesonide/Glycopyr/Formoterol16$11,742
SymbicortBudesonide/Formoterol Fumarate30$8,909
Spiriva RespimatTiotropium Bromide16$8,478
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog11$8,436
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr15$8,076

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Combivent Respimat, Spiriva Respimat$32$70,57270 claims
Novo NordiskOzempic$70$68,58063 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$146$67,71390 claims
AbbVieLinzess, Synthroid$28$35,42844 claims
Lilly USA, LLCTrulicity$73$32,28532 claims
GSKTrelegy Ellipta, Anoro Ellipta$46$26,97835 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 4,522 family providers in North Carolina.

Other family in Mount Airy

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →